<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02843438</url>
  </required_header>
  <id_info>
    <org_study_id>38RC09.014</org_study_id>
    <nct_id>NCT02843438</nct_id>
  </id_info>
  <brief_title>Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis</brief_title>
  <acronym>BIOLUVE</acronym>
  <official_title>Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Toxoplasmosis affects one to two newborn each 10000 births. Among them, 1 to 2 % develop
      learning disabilities or die, and 4 to 27 % develop a chorioretinitis sometimes leading to an
      amblyopia responsible for visual impairment. Toxoplasmosis uveitis affects too adults
      immunocompetent and immunodepressed who have had an acquired toxoplasmosis. Clinical
      diagnosis of ocular toxoplasmosis is more complicated in presence of posterior
      neuro-retinitis, inflammation of the papilla, uveitis without chorioretinitis, fuchs
      heterochromic iridocyclitis, scleritis, diffuse necrotizing or multifocal retinitis. In this
      situation biological markers diagnostic and prognostic of toxoplasmosis uveitis are useful.

      Highly kept molecules (during evolution) like stress proteins (Hsp) are are found in the host
      and the pathogen and there can trigger a crossed immune response. Stress proteins haven't
      been explored yet, in the context of toxoplasmosis uveitis on humans.

      The hypothesis is that Hsp70 and antibodies anti-Hsp70 are diagnostic and prognostic markers
      of ocular toxoplasmosis.

      The goal is to evaluate diagnosis value of biological markers (Hsp70 and antibodies IgG
      anti-Hsp70) in toxoplasmosis uveitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ELISA tests</measure>
    <time_frame>About an hour</time_frame>
    <description>ELISA (enzyme linked immunosorbent assay) tests. Biological markers evaluation : stress protein Hsp70 and antibodies anti-Hsp70.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Subjects Clinically Suspected an Active Source of Toxoplasmosis Chorioretinitis Infection</condition>
  <arm_group>
    <arm_group_label>Subjects suspected of toxoplasmosis chorioretinitis infection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects clinically suspected at least of one active source of toxoplasmosis chorioretinitis infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fluorescein angiography</intervention_name>
    <arm_group_label>Subjects suspected of toxoplasmosis chorioretinitis infection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dilated fundus examination</intervention_name>
    <arm_group_label>Subjects suspected of toxoplasmosis chorioretinitis infection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Toxoplasmosis serology</intervention_name>
    <arm_group_label>Subjects suspected of toxoplasmosis chorioretinitis infection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-toxoplasmosis treatment</intervention_name>
    <arm_group_label>Subjects suspected of toxoplasmosis chorioretinitis infection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-inflammatory treatments</intervention_name>
    <arm_group_label>Subjects suspected of toxoplasmosis chorioretinitis infection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Puncture in anterior chamber</intervention_name>
    <arm_group_label>Subjects suspected of toxoplasmosis chorioretinitis infection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years

          -  Subjects clinically suspected at least of one active source of toxoplasmosis
             chorioretinitis infection

          -  Persons affiliated to national social security

        Exclusion Criteria:

          -  Pregnant, parturient or breastfeeding women

          -  Persons deprived of liberty by judicial or administrative decision, person under legal
             protection

          -  Refusal by a patient to do the PCA (anterior chamber puncture)

          -  Patients whose following will be difficult or nonexistent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence Bouillet, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grenoble Hospital University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UniversityHospitalGrenoble</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bonfioli AA, Orefice F. Toxoplasmosis. Semin Ophthalmol. 2005 Jul-Sep;20(3):129-41. Review.</citation>
    <PMID>16282146</PMID>
  </reference>
  <reference>
    <citation>Bouillet L, Sarrot-Reynauld F, Gonzalvez B, Massot C, Romanet J, Mouillon M. [Diagnostic strategy in uveitis: a prospective study in 125 cases]. J Fr Ophtalmol. 2000 Jun;23(6):569-75. French.</citation>
    <PMID>10880922</PMID>
  </reference>
  <reference>
    <citation>Brenier-Pinchart MP, Morand-Bui V, Fricker-Hidalgo H, Equy V, Marlu R, Pelloux H. Adapting a conventional PCR assay for Toxoplasma gondii detection to real-time quantitative PCR including a competitive internal control. Parasite. 2007 Jun;14(2):149-54.</citation>
    <PMID>17645187</PMID>
  </reference>
  <reference>
    <citation>Chen M, Aosai F, Norose K, Mun HS, Yano A. The role of anti-HSP70 autoantibody-forming V(H)1-J(H)1 B-1 cells in Toxoplasma gondii-infected mice. Int Immunol. 2003 Jan;15(1):39-47.</citation>
    <PMID>12502724</PMID>
  </reference>
  <reference>
    <citation>Chumpitazi BF, Boussaid A, Pelloux H, Racinet C, Bost M, Goullier-Fleuret A. Diagnosis of congenital toxoplasmosis by immunoblotting and relationship with other methods. J Clin Microbiol. 1995 Jun;33(6):1479-85.</citation>
    <PMID>7650171</PMID>
  </reference>
  <reference>
    <citation>Chumpitazi BF, Bouillet L, Drouet MT, Kuhn L, Garin J, Zarski JP, Drouet C. Biological autoimmunity screening in hepatitis C patients by anti-HepG2 lysate and anti-heat shock protein 70.1 autoantibodies. Eur J Clin Microbiol Infect Dis. 2009 Feb;28(2):137-46. doi: 10.1007/s10096-008-0599-y. Epub 2008 Aug 12.</citation>
    <PMID>18696130</PMID>
  </reference>
  <reference>
    <citation>Delair E, Monnet D, Grabar S, Dupouy-Camet J, Yera H, Brézin AP. Respective roles of acquired and congenital infections in presumed ocular toxoplasmosis. Am J Ophthalmol. 2008 Dec;146(6):851-5. doi: 10.1016/j.ajo.2008.06.027. Epub 2008 Aug 23.</citation>
    <PMID>18723143</PMID>
  </reference>
  <reference>
    <citation>Derouin F, Bultel C, Roze S. (Coordination rédactionnelle). Toxoplasmose: état des connaissances et évaluation du risque lié à l'alimentation. Rapport du groupe de travail &quot; Toxoplasma gondii &quot; de l'Afssa. Coordination éditoriale : Thomann C &amp; Ribeiro F. AFSSA Déc. 2005, pp318.</citation>
  </reference>
  <reference>
    <citation>Desmonts G. Definitive serological diagnosis of ocular toxoplasmosis. Arch Ophthalmol. 1966 Dec;76(6):839-51.</citation>
    <PMID>5924940</PMID>
  </reference>
  <reference>
    <citation>Direskeneli H, Saruhan-Direskeneli G. The role of heat shock proteins in Behçet's disease. Clin Exp Rheumatol. 2003 Jul-Aug;21(4 Suppl 30):S44-8. Review.</citation>
    <PMID>14727460</PMID>
  </reference>
  <reference>
    <citation>Echeverria PC, Matrajt M, Harb OS, Zappia MP, Costas MA, Roos DS, Dubremetz JF, Angel SO. Toxoplasma gondii Hsp90 is a potential drug target whose expression and subcellular localization are developmentally regulated. J Mol Biol. 2005 Jul 22;350(4):723-34.</citation>
    <PMID>15967463</PMID>
  </reference>
  <reference>
    <citation>Fang H, Aosai F, Mun HS, Norose K, Ahmed AK, Furuya M, Yano A. Anaphylactic reaction induced by Toxoplasma gondii-derived heat shock protein 70. Int Immunol. 2006 Oct;18(10):1487-97. Epub 2006 Aug 30.</citation>
    <PMID>16943259</PMID>
  </reference>
  <reference>
    <citation>Holland GN. Reconsidering the pathogenesis of ocular toxoplasmosis. Am J Ophthalmol. 1999 Oct;128(4):502-5. Review.</citation>
    <PMID>10577593</PMID>
  </reference>
  <reference>
    <citation>Imamura Y, Kurokawa MS, Yoshikawa H, Nara K, Takada E, Masuda C, Tsukikawa S, Ozaki S, Matsuda T, Suzuki N. Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet's disease. Clin Exp Immunol. 2005 Feb;139(2):371-8.</citation>
    <PMID>15654837</PMID>
  </reference>
  <reference>
    <citation>Kodjikian L, Wallon M, Fleury J, Denis P, Binquet C, Peyron F, Garweg JG. Ocular manifestations in congenital toxoplasmosis. Graefes Arch Clin Exp Ophthalmol. 2006 Jan;244(1):14-21. Epub 2005 May 20.</citation>
    <PMID>15906073</PMID>
  </reference>
  <reference>
    <citation>Lyons RE, Johnson AM. Heat shock proteins of Toxoplasma gondii. Parasite Immunol. 1995 Jul;17(7):353-9.</citation>
    <PMID>8552407</PMID>
  </reference>
  <reference>
    <citation>Maubon D, Ajzenberg D, Brenier-Pinchart MP, Dardé ML, Pelloux H. What are the respective host and parasite contributions to toxoplasmosis? Trends Parasitol. 2008 Jul;24(7):299-303. doi: 10.1016/j.pt.2008.03.012. Epub 2008 May 29.</citation>
    <PMID>18514029</PMID>
  </reference>
  <reference>
    <citation>Pelloux H, Mouillon M, Romanet JP, Reynier P, Ligeon P, Goullier-Fleuret A, Ambroise-Thomas P. [Ocular toxoplasmosis. Comparison between two biological methods to study aqueous humor]. Presse Med. 1991 Oct 26;20(34):1655-8. French.</citation>
    <PMID>1836568</PMID>
  </reference>
  <reference>
    <citation>Quintana FJ, Cohen IR. Heat shock proteins as endogenous adjuvants in sterile and septic inflammation. J Immunol. 2005 Sep 1;175(5):2777-82. Review.</citation>
    <PMID>16116161</PMID>
  </reference>
  <reference>
    <citation>SenGupta D, Norris PJ, Suscovich TJ, Hassan-Zahraee M, Moffett HF, Trocha A, Draenert R, Goulder PJ, Binder RJ, Levey DL, Walker BD, Srivastava PK, Brander C. Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II. J Immunol. 2004 Aug 1;173(3):1987-93.</citation>
    <PMID>15265933</PMID>
  </reference>
  <reference>
    <citation>Silva NM, Gazzinelli RT, Silva DA, Ferro EA, Kasper LH, Mineo JR. Expression of Toxoplasma gondii-specific heat shock protein 70 during In vivo conversion of bradyzoites to tachyzoites. Infect Immun. 1998 Aug;66(8):3959-63.</citation>
    <PMID>9673286</PMID>
  </reference>
  <reference>
    <citation>Wang XH, Qin Y, Hu MH, Xie Y. Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma (HCC) induce specific cytotoxic T lymphocytes. Cancer Immunol Immunother. 2005 Oct;54(10):971-80. Epub 2005 Jun 18.</citation>
    <PMID>15965645</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2016</study_first_submitted>
  <study_first_submitted_qc>July 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2016</study_first_posted>
  <last_update_submitted>July 22, 2016</last_update_submitted>
  <last_update_submitted_qc>July 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Toxoplasmosis</keyword>
  <keyword>Uveitis</keyword>
  <keyword>Chorioretinitis</keyword>
  <keyword>Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Toxoplasmosis</mesh_term>
    <mesh_term>Chorioretinitis</mesh_term>
    <mesh_term>Toxoplasmosis, Ocular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

